<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503513</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00137086</org_study_id>
    <nct_id>NCT03503513</nct_id>
  </id_info>
  <brief_title>Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury</brief_title>
  <official_title>The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cross over study evaluating the efficacy of intravesical gentamicin on the occurrence rate&#xD;
      of urinary tract infections and bladder complications in patients after spinal cord injury&#xD;
      (SCI), and to assess its effectiveness in promoting overall quality of life (QOL), community&#xD;
      living, and participation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of urinary tract infections (UTI)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of reported urinary tract infections (UTI) by participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in score of Neurogenic Bladder Symptom Severity scale</measure>
    <time_frame>6 months</time_frame>
    <description>Self-reported bladder symptoms on a scale from 0 (no symptoms) to 74 (maximum symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of Neurogenic Bowel Dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>Self-reported bowel symptoms on a scale from 0 (very minor) to 14+ (severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Spinal Cord Injuries</condition>
  <condition>Spinal Cord Diseases</condition>
  <condition>Neurogenic Bladder</condition>
  <arm_group>
    <arm_group_label>Gentamicin sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin Sulfate</intervention_name>
    <description>Gentamicin will be compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Participants will do daily instillations of 30 milliliters of solution</description>
    <arm_group_label>Gentamicin sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form.&#xD;
&#xD;
          -  History of traumatic spinal cord injury (SCI) or non-traumatic spinal cord disease,&#xD;
             (SCD) with sustained neurological dysfunction&#xD;
&#xD;
          -  At least 6 months post-initial hospital discharge following SCI/SCD onset&#xD;
&#xD;
          -  Neurogenic bladder&#xD;
&#xD;
          -  Ability to perform daily instillation on self or with help of others and willingness&#xD;
             to adhere to the study regiment.&#xD;
&#xD;
          -  History of at least 2 documented urinary tract infection (UTI) during the previous 6&#xD;
             months (prior to screening)&#xD;
&#xD;
          -  Have a designated physician or health care provider for routine care&#xD;
&#xD;
          -  Use of clean intermittent catheterization or catheterization through a stoma (i.e.&#xD;
             Mitrofanoff) as their primary method of bladder management&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent use of systemic oral or intravesical antibiotic prophylaxis&#xD;
&#xD;
          -  Documented or self-reported history of gentamicin allergy&#xD;
&#xD;
          -  Female patients who are currently pregnant or attempting to become pregnant&#xD;
&#xD;
          -  Patients with a history of 8th cranial nerve disorder&#xD;
&#xD;
          -  Co-morbidities like cancer and chronic disease that could impact patient safety OR&#xD;
             significantly affect the rate of UTIs and/or quality of life (QOL) substantially&#xD;
&#xD;
          -  Urological co-morbidities like bladder cancer and history of kidney disease.&#xD;
&#xD;
          -  Current UTI at baseline visit (assessed via urine analysis and culture and symptoms)&#xD;
&#xD;
          -  Concurrent enrollment in a similar clinical trial&#xD;
&#xD;
          -  Concurrent use of contraindicated diuretics (ethacrynic acid, furosemide)&#xD;
&#xD;
          -  Current use of other contraindicated or disallowed concomitant medications or&#xD;
             receiving treatments that may influence the results from this study.&#xD;
&#xD;
          -  Known allergy to aminoglycoside antibiotics&#xD;
&#xD;
          -  At the discretion of study team, individuals who are unable or unlikely to comply with&#xD;
             procedures and/or for whom study participation is not recommended (e.g. unable to&#xD;
             arrange transportation, cognitive and/or behavioral challenges that preclude&#xD;
             meaningful participation, poor health, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Tate, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Pelletier-Cameron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrienne Roth, BA</last_name>
    <phone>(734) 936-7949</phone>
    <email>adbpo@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Forchheimer, MPP</last_name>
    <phone>(734) 936-7949</phone>
    <email>forchm@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Roth, BA</last_name>
      <email>adbpo@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marty Forchheimer</last_name>
      <email>forchm@med.umich.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Denise Tate, PhD</investigator_full_name>
    <investigator_title>Professor of Physical Medicine and Rehabilitation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

